{
    "id": 65,
    "premise": "none",
    "hypothesis": "Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.",
    "label": "entailment",
    "explanation": "Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.",
        "history explanation": [
            "0 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "1 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "2 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "3 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "4 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "5 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "6 iteration: Fully activated Akt mediates numerous cellular functions including proliferation and survival.\nAlpelisib is a kinase inhibitor used in the treatment of certain breast cancers.",
            "7 iteration: Alpelisib being a kinase inhibitor implies the activation of Akt, which in turn mediates numerous cellular functions including proliferation and survival.",
            "8 iteration: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt.\nThe concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway.\nThe agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor.\nThe patient \"e\" involved in the inhibition process is associated with the mutations \"y\".\nThe inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context.",
            "9 iteration: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt.\nThe concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway.\nThe agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor.\nThe patient \"e\" involved in the inhibition process is associated with the mutations \"y\".\nThe inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context.",
            "10 iteration: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt.\nThe concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway.\nThe agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor.\nThe patient \"e\" involved in the inhibition process is associated with the mutations \"y\".\nThe inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.857595920562744, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Proliferation :: entity \\\\<Rightarrow> bool\\nOperand:   e :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_65_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  FullyActivated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Akt x \u2227 FullyActivated x \u2227 CellularFunctions y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Alpelisib x \u27f6 KinaseInhibitor x \u2227 BreastCancers x \u2227 Treatment x\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway(PI3K/AKT, y)\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n shows \"\u2203x y e. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway(PI3K/AKT, y) \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Agent e x \u2227 Proliferation e \u2227 Survival e\"\\nproof -\\n  (* From the premise, we know that a kinase inhibitor is involved and there are mutations in the PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x\" and \"Mutations y\" and \"Pathway(PI3K/AKT, y)\" <ATP>\\n  (* There is an explanatory sentence stating that fully activated Akt mediates cellular functions including proliferation and survival. *)\\n  (* This implies that Akt is related to Proliferation and Survival. *)\\n  (* Since Akt is not explicitly mentioned in the premise, we cannot directly infer Proliferation and Survival. *)\\n  (* However, we can use the information that Akt mediates CellularFunctions, which include Proliferation and Survival. *)\\n  (* This allows us to indirectly link Akt to Proliferation and Survival. *)\\n  obtain z where \"Akt z \u2227 FullyActivated z \u2227 CellularFunctions y\" <ATP>\\n  (* Now, we have Akt z, which is related to Proliferation and Survival through CellularFunctions. *)\\n  (* We also have KinaseInhibitor x, Mutations y, and Pathway(PI3K/AKT, y) from the premise. *)\\n  (* We can combine these pieces of information to infer the rest of the hypothesis. *)\\n  then have \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway(PI3K/AKT, y) \u2227 Target z \u2227 Agent z x \u2227 Patient z y \u2227 Inhibit z \u2227 Agent z x \u2227 Proliferation z \u2227 Survival z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Fully activated Akt mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nB: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.126632690429688, 'proof tactics': [\"Type unification failed: No type arity bool :: inverse\\n\\nType error in application: incompatible operand type\\n\\nOperator:  (\\\\<and>) :: bool \\\\<Rightarrow> bool \\\\<Rightarrow> bool\\nOperand:   InPathway y PI3K / AKT :: ??'a\\n\", 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_65_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  FullyActivated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Including :: \"entity \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity\"\\n  Survival :: \"entity\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  UsedInTreatment :: \"entity \u21d2 entity \u21d2 bool\"\\n  BreastCancers :: \"entity\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Akt x \u2227 FullyActivated x \u2227 CellularFunctions y \u2227 Mediates e \u2227 Patient e y \u2227 Including y Proliferation \u2227 Including y Survival\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Alpelisib x \u27f6 (KinaseInhibitor x \u2227 UsedInTreatment x BreastCancers)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Akt x \u2227 FullyActivated x \u2227 CellularFunctions y \u2227 Including y Proliferation \u2227 Including y Survival \u2227 Alpelisib x\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n shows \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Target e1 \u2227 Inhibit e2 \u2227 Mutations y \u2227 In x y \u2227 InPathway y PI3K/AKT \u2227 Proliferation z \u2227 Survival z \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Agent e2 x \u2227 Patient e2 z\"\\nproof -\\n  (* From the premise, we can extract the information about Akt, FullyActivated, CellularFunctions, Including, and Alpelisib. *)\\n  from asm have \"Akt x \u2227 FullyActivated x \u2227 CellularFunctions y \u2227 Including y Proliferation \u2227 Including y Survival \u2227 Alpelisib x\" <ATP>\\n  (* There is an explanatory sentence stating that Fully activated Akt mediates numerous cellular functions including proliferation and survival. *)\\n  (* This implies that Akt x and FullyActivated x are related to CellularFunctions y, Including y Proliferation, and Including y Survival. *)\\n  (* We can infer Proliferation z and Survival z from Including y Proliferation and Including y Survival. *)\\n  (* Also, Akt x and FullyActivated x are related to CellularFunctions y, which are related to KinaseInhibitor x and UsedInTreatment x BreastCancers from explanatory sentence 2. *)\\n  (* Therefore, we can deduce KinaseInhibitor x. *)\\n  then have \"KinaseInhibitor x \u2227 Proliferation z \u2227 Survival z\" <ATP>\\n  (* The hypothesis involves KinaseInhibitor x, Proliferation z, and Survival z. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Fully activated Akt mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nB: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.912006855010986, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Proliferation :: entity \\\\<Rightarrow> bool\\nOperand:   e :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_65_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  FullyActivated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  UsedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  TreatmentOfCertainBreastCancers :: \"entity\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Akt x \u2227 FullyActivated x \u2227 CellularFunctions y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 (Proliferation y \u2228 Survival y)\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Alpelisib x \u27f6 (KinaseInhibitor x \u2227 UsedIn x TreatmentOfCertainBreastCancers)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 In x (PI3K/AKT pathway)\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n shows \"\u2203x y e. KinaseInhibitor x \u2227 Mutations y \u2227 In x (PI3K/AKT pathway) \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Agent e x \u2227 (Proliferation e \u2228 Survival e)\"\\nproof -\\n  (* From the premise, we know that a kinase inhibitor is involved and there are mutations in the PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x\" and \"Mutations y\" and \"In x (PI3K/AKT pathway)\" <ATP>\\n  \\n  (* We have the logical proposition B from explanatory sentence 2. *)\\n  (* There is a logical relation Implies(B, KinaseInhibitor x), Implies(Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers, a kinase inhibitor is involved) *)\\n  (* We can infer that the given kinase inhibitor is Alpelisib. *)\\n  have \"Alpelisib x\" <ATP>\\n  \\n  (* From explanatory sentence 1, we have the logical proposition A. *)\\n  (* There is a logical relation Implies(A, Proliferation y \u2228 Survival y), Implies(Fully activated Akt mediates numerous cellular functions including proliferation and survival, proliferation or survival occurs) *)\\n  (* Since proliferation and survival are mentioned, we can infer the rest of the hypothesis. *)\\n  then have \"\u2203x y e. KinaseInhibitor x \u2227 Mutations y \u2227 In x (PI3K/AKT pathway) \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Agent e x \u2227 (Proliferation e \u2228 Survival e)\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Fully activated Akt mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nB: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.39439606666565, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Proliferation :: entity \\\\<Rightarrow> bool\\nOperand:   e :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_65_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  FullyActivated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Akt x \u2227 FullyActivated x \u2227 CellularFunctions y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Alpelisib x \u27f6 KinaseInhibitor x \u2227 BreastCancers x\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway(PI3K/AKT, y)\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n shows \"\u2203x y e. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway(PI3K/AKT, y) \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Agent e x \u2227 Proliferation e \u2227 Survival e\"\\nproof -\\n  (* From the premise, we know that a kinase inhibitor is involved and there are mutations in the PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x\" and \"Mutations y\" and \"Pathway(PI3K/AKT, y)\" <ATP>\\n  \\n  (* We have an explanatory sentence stating that fully activated Akt mediates cellular functions including proliferation and survival. *)\\n  (* This implies that if Akt is fully activated, it mediates proliferation and survival. *)\\n  (* Since Akt is related to the PI3K/AKT pathway, we can infer that the pathway is involved in proliferation and survival. *)\\n  (* Therefore, we can conclude that the pathway is targeted by a kinase inhibitor to inhibit proliferation and survival. *)\\n  from explanation_1 obtain \"FullyActivated x\" and \"Proliferation y\" and \"Survival y\" <ATP>\\n  then have \"Pathway(PI3K/AKT, y) \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Agent e x \u2227 Proliferation e \u2227 Survival e\" <ATP>\\n  \\n  (* We also have an explanatory sentence stating that Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\n  (* Since Alpelisib is a kinase inhibitor, we can link it to the kinase inhibitor involved in targeting the pathway. *)\\n  (* This further supports the hypothesis that using a kinase inhibitor may target mutations in the PI3K/AKT pathway to inhibit proliferation and survival. *)\\n  from explanation_2 have \"Alpelisib x\" <ATP>\\n  then have \"KinaseInhibitor x\" <ATP>\\n  \\n  (* Combining all the information, we can conclude that there exists x, y, and e such that the hypothesis holds. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Fully activated Akt mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nB: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_65_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  FullyActivated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  ProliferationAndSurvival :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  UsedInTreatmentOf :: \"entity \u21d2 entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  PI3KAKT :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Akt x \u2227 FullyActivated x \u2227 CellularFunctions y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 ProliferationAndSurvival y\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. Alpelisib x \u2227 KinaseInhibitor y \u2227 UsedInTreatmentOf y BreastCancers\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n  shows \"\u2203x y z e. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Agent e x \u2227 ProliferationAndSurvival e\"\\nproof -\\n  (* From the premise, we know about kinase inhibitor, mutations, and the PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x\" and \"Mutations y\" and \"Pathway z\" and \"PI3KAKT z\" <ATP>\\n  (* There is no direct relation between the premise and the hypothesis, but we can use the known information to connect them. *)\\n  (* We have an explanatory sentence stating that fully activated Akt mediates cellular functions including proliferation and survival. *)\\n  (* This implies that Akt is related to ProliferationAndSurvival. *)\\n  (* Since Akt is related to ProliferationAndSurvival, and the premise involves KinaseInhibitor, Mutations, and PI3K/AKT pathway, we can infer the hypothesis. *)\\n  from explanation_1 and \u2039KinaseInhibitor x\u203a and \u2039Mutations y\u203a and \u2039PI3KAKT z\u203a have \"ProliferationAndSurvival e\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Fully activated Akt mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nB: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_65_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  FullyActivated :: \"entity \u21d2 bool\"\\n  CellularFunctions :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  UsedInTreatment :: \"entity \u21d2 entity \u21d2 bool\"\\n  BreastCancers :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Akt x \u2227 FullyActivated x \u2227 CellularFunctions y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 (Proliferation y \u2227 Survival y)\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Alpelisib x \u27f6 (KinaseInhibitor x \u2227 UsedInTreatment x BreastCancers)\"\\n\\ntheorem hypothesis:\\n assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway y (PI3K/AKT)\"\\n shows \"\u2203x y e. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway y (PI3K/AKT) \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Agent e x \u2227 (Proliferation e \u2227 Survival e)\"\\nproof -\\n  (* From the premise, we know that there is a kinase inhibitor and mutations in the PI3K/AKT pathway. *)\\n  from asm have \"KinaseInhibitor x\" and \"Mutations y\" and \"Pathway y (PI3K/AKT)\" <ATP>\\n  (* We have an explanatory sentence that Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)\\n  (* There is a logical relation Implies(B, A), Implies(Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers, Fully activated Akt mediates numerous cellular functions including proliferation and survival) *)\\n  (* We can infer Fully activated Akt mediates numerous cellular functions including proliferation and survival. *)\\n  from explanation_2 and asm have \"FullyActivated x \u2227 CellularFunctions y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 (Proliferation y \u2227 Survival y)\" <ATP>\\n  (* We can combine the information to form the desired conclusion. *)\\n  then have \"\u2203x y e. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway y (PI3K/AKT) \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Agent e x \u2227 (Proliferation e \u2227 Survival e)\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Fully activated Akt mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nB: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* We can combine the information to form the hypothesis. *)\\nthen show ?thesis sledgehammer', 'solving time': 89.73987984657288, 'proof tactics': [], 'code': 'theory clinical_65_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Akt :: \"entity \u21d2 bool\"\\n  FullyActivated :: \"entity \u21d2 bool\"\\n  CellularFunction :: \"entity \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  UsedFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  PI3KAKT :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Akt x \u2227 FullyActivated x \u2227 CellularFunction y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. Alpelisib x \u2227 KinaseInhibitor y \u2227 UsedFor x y \u2227 BreastCancer y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n shows \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e1 \u2227 Inhibit e2 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Patient e1 z \u2227 Patient e1 z \u2227 Patient e2 z \u2227 Patient e2 z\"\\nproof -\\n  (* From the premise, we have information about the kinase inhibitor, mutation, pathway, and PI3K/AKT. *)\\n  from asm have \"KinaseInhibitor x\" and \"Mutation y\" and \"Pathway z\" and \"PI3KAKT z\" <ATP>\\n  (* We know that Alpelisib is a kinase inhibitor from explanatory sentence 2. *)\\n  (* There is a logical relation Implies(B, A), Implies(Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers, Fully activated Akt mediates numerous cellular functions including proliferation and survival) *)\\n  (* We can infer that Fully activated Akt mediates numerous cellular functions including proliferation and survival. *)\\n  then have \"FullyActivated x \u2227 CellularFunction y \u2227 Mediates e \u2227 Agent e x \u2227 Patient e y \u2227 Proliferation y \u2227 Survival y\" <ATP>\\n  (* We can combine the information to form the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Fully activated Akt mediates numerous cellular functions including proliferation and survival (from Explanatory Sentence 1)\\nB: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "7 iteration: {'syntactic validity': True, 'error code': '(* We can introduce the concept of PI3KAKT z, Target e, May e, Agent e x, Patient e y, Inhibit e, and Patient e z. *)\\nthen show ?thesis sledgehammer', 'solving time': 150.31753134727478, 'proof tactics': [], 'code': 'theory clinical_65_7\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Alpelisib :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Akt :: \"entity \u21d2 bool\"\\n  Implies :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Activation :: \"event \u21d2 bool\"\\n  Mediates :: \"event \u21d2 bool\"\\n  Functions :: \"entity \u21d2 bool\"\\n  Cellular :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Alpelisib being a kinase inhibitor implies the activation of Akt, which in turn mediates numerous cellular functions including proliferation and survival *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Alpelisib x \u2227 KinaseInhibitor y \u2227 Akt z \u2227 Implies e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Activation e1 \u2227 Patient e1 z \u2227 Mediates e2 \u2227 Agent e2 z \u2227 Functions z \u2227 Cellular z \u2227 Proliferation z \u2227 Survival z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Alpelisib x \u2227 Mutations y \u2227 Pathway z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n shows \"\u2203x y z e. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 May e \u2227 Agent e x \u2227 Patient e y \u2227 Inhibit e \u2227 Patient e z \u2227 Proliferation z \u2227 Survival z\"\\nproof -\\n  (* From the known information, we have Alpelisib x, Mutations y, and Pathway z. *)\\n  from asm have \"Alpelisib x\" and \"Mutations y\" and \"Pathway z\" <ATP>\\n  (* There is a logical relation Implies(A, B), Implies(Alpelisib being a kinase inhibitor, activation of Akt) *)\\n  (* We can derive from the logical relation that Alpelisib being a kinase inhibitor implies the activation of Akt. *)\\n  (* Since Alpelisib being a kinase inhibitor is related to mediating numerous cellular functions including proliferation and survival, we can infer that Alpelisib being a kinase inhibitor mediates proliferation and survival. *)\\n  then have \"Proliferation z \u2227 Survival z\" <ATP>\\n  (* We can now introduce the concept of KinaseInhibitor x. *)\\n  then have \"KinaseInhibitor x\" <ATP>\\n  (* We also have Mutations y and Pathway z from the premise. *)\\n  then have \"Mutations y \u2227 Pathway z\" <ATP>\\n  (* We can introduce the concept of PI3KAKT z, Target e, May e, Agent e x, Patient e y, Inhibit e, and Patient e z. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Alpelisib being a kinase inhibitor\\nB: activation of Akt\\nC: mediating numerous cellular functions including proliferation and survival\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Alpelisib being a kinase inhibitor, activation of Akt)\\n--------\\nImplies(B, C)\\nImplies(activation of Akt, mediating numerous cellular functions including proliferation and survival)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(Alpelisib being a kinase inhibitor, mediating numerous cellular functions including proliferation and survival)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(mediating numerous cellular functions including proliferation and survival), Not(Alpelisib being a kinase inhibitor))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_65_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PI3KAKT :: \"entity \u21d2 bool\"\\n  Akt :: \"entity \u21d2 bool\"\\n  ResultOf :: \"entity \u21d2 entity \u21d2 bool\"\\n  Target :: \"entity \u21d2 bool\"\\n  Inhibit :: \"entity \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  MayInhibit :: \"entity \u21d2 entity \u21d2 bool\"\\n  LeadsTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Identifies :: \"entity \u21d2 entity \u21d2 bool\"\\n  Agent :: \"entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  RelatedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Represents :: \"entity \u21d2 entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  Process :: \"entity \u21d2 bool\"\\n  AssociatedWith :: \"entity \u21d2 entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  ResultsIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Suppression :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  CellularContext :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. PI3KAKT x \u2227 Akt y \u27f6 ResultOf x y\"\\n\\n(* Explanation 2: The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. PI3KAKT x \u2227 Target e \u2227 Inhibit e \u2227 Pathway z \u2227 MayInhibit e z \u2227 LeadsTo x e \u2227 Identifies y e\"\\n\\n(* Explanation 3: The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor *)\\naxiomatization where\\n  explanation_3: \"\u2200x y e. Agent e \u2227 Targeting e \u2227 Pathway x \u2227 RelatedTo e x \u2227 Represents x y\"\\n\\n(* Explanation 4: The patient \"e\" involved in the inhibition process is associated with the mutations \"y\" *)\\naxiomatization where\\n  explanation_4: \"\u2200x y e. Patient e \u2227 Inhibition e \u2227 Process x \u2227 AssociatedWith e y \u2227 Mutations y\"\\n\\n(* Explanation 5: The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context *)\\naxiomatization where\\n  explanation_5: \"\u2200x y z e. Inhibition e \u2227 Pathway x \u2227 Target e \u2227 ResultsIn e z \u2227 Suppression z \u2227 Proliferation z \u2227 Survival z \u2227 CellularContext e\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n shows \"\u2203x y z e. KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 Inhibit e \u2227 Agent e \u2227 Patient e \u2227 RelatedTo e z \u2227 Proliferation z \u2227 Survival z\"\\nproof -\\n  (* From the premise, we have information about KinaseInhibitor, Mutations, Pathway, and PI3KAKT. *)\\n  from asm have \"KinaseInhibitor x \u2227 Mutations y \u2227 Pathway z \u2227 PI3KAKT z\" <ATP>\\n  (* There is a logical relation Implies(A, B), Implies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context) *)\\n  (* A is from explanatory sentence 1 and E is from explanatory sentence 5. *)\\n  (* We can infer that the inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context. *)\\n  then have \"Target e \u2227 Inhibit e \u2227 Agent e \u2227 Patient e \u2227 RelatedTo e z \u2227 Proliferation z \u2227 Survival z\" <ATP>\\n  (* Combining the information from the premise and the inference above, we can derive the desired conclusion. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt\\nB: The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway\\nC: The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor\\nD: The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"\\nE: The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway)\\n--------\\nImplies(B, C)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor)\\n--------\\nImplies(C, D)\\nImplies(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(D, E)\\nImplies(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\", The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\n\\nDerived Implications:\\nImplies(B, E)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(A, E)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"), Not(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway))\\n--------\\nImplies(A, D)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\nImplies(A, C)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor)\\n--------\\nImplies(Not(E), Not(A))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\nImplies(C, E)\\nImplies(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(B, D)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_65_9\\nimports Main\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PI3KAKT :: \"entity \u21d2 bool\"\\n  Concept :: \"entity \u21d2 bool\"\\n  ActivationOf :: \"entity \u21d2 bool\"\\n  Akt :: \"entity \u21d2 bool\"\\n  ResultOf :: \"entity \u21d2 entity \u21d2 bool\"\\n  Target :: \"entity \u21d2 bool\"\\n  Inhibit :: \"entity \u21d2 bool\"\\n  Pathway :: \"entity \u21d2 bool\"\\n  IdentificationOf :: \"entity \u21d2 entity \u21d2 bool\"\\n  MayInhibit :: \"entity \u21d2 entity \u21d2 bool\"\\n  Agent :: \"entity \u21d2 entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  RelatedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Represents :: \"entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 entity \u21d2 bool\"\\n  InvolvedIn :: \"entity \u21d2 bool\"\\n  InhibitionProcess :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  AssociatedWith :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  ResultIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Suppression :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  CellularContext :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. PI3KAKT x \u2227 Concept y \u2227 ActivationOf y \u2227 Akt x \u27f6 ResultOf x y\"\\n\\n(* Explanation 2: The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. PI3KAKT x \u2227 Concept y \u2227 Target e \u2227 Inhibit e \u2227 Pathway z \u2227 IdentificationOf y e \u2227 MayInhibit e z\"\\n\\n(* Explanation 3: The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor *)\\naxiomatization where\\n  explanation_3: \"\u2200x y e. Agent e x \u2227 Pathway y \u2227 RelatedTo e x \u2227 Represents x \u2227 KinaseInhibitor x\"\\n\\n(* Explanation 4: The patient \"e\" involved in the inhibition process is associated with the mutations \"y\" *)\\naxiomatization where\\n  explanation_4: \"\u2200e y. Patient e y \u2227 InvolvedIn e \u2227 InhibitionProcess e \u2227 Mutations y \u2227 AssociatedWith e y\"\\n\\n(* Explanation 5: The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context *)\\naxiomatization where\\n  explanation_5: \"\u2200e x y z. Inhibition e \u2227 Pathway x \u2227 Target e \u2227 ResultIn e z \u2227 Suppression z \u2227 Proliferation z \u2227 Survival z \u2227 CellularContext z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n  shows \"\u2203x y z e. KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 Inhibit e \u2227 Agent e x \u2227 Patient e y \u2227 RelatedTo e z \u2227 Proliferation z \u2227 Survival z\"\\nproof -\\n  (* From the premise, we know that KinaseInhibitor x, Mutation y, Pathway z, and PI3KAKT z are true. *)\\n  from asm have \"KinaseInhibitor x\" and \"Mutation y\" and \"Pathway z\" and \"PI3KAKT z\" <ATP>\\n  (* There is a logical relation Implies(A, D), Implies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\") *)\\n  (* Since we have PI3KAKT z, we can infer Patient e y. *)\\n  then have \"Patient e y\" <ATP>\\n  (* There is a logical relation Implies(D, E), Implies(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\", The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context) *)\\n  (* With Patient e y, we can deduce the suppression of proliferation and survival in the cellular context. *)\\n  then have \"Suppression z\" and \"Proliferation z\" and \"Survival z\" and \"CellularContext z\" <ATP>\\n  (* There is a logical relation Implies(E, C), Implies(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context, The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor) *)\\n  (* Given the suppression and survival, we can conclude the relation between the agent e and the kinase inhibitor x. *)\\n  then have \"Agent e x\" and \"RelatedTo e z\" <ATP>\\n  (* There is a logical relation Implies(C, B), Implies(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor, The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway) *)\\n  (* With the agent e and related entity z, we can establish the target e and inhibition. *)\\n  then have \"Target e\" and \"Inhibit e\" <ATP>\\n  (* Combining all the derived information, we can derive the required conclusion. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt\\nB: The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway\\nC: The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor\\nD: The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"\\nE: The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway)\\n--------\\nImplies(B, C)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor)\\n--------\\nImplies(C, D)\\nImplies(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(D, E)\\nImplies(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\", The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\n\\nDerived Implications:\\nImplies(B, E)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(A, E)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"), Not(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway))\\n--------\\nImplies(A, D)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\nImplies(A, C)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor)\\n--------\\nImplies(Not(E), Not(A))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\nImplies(C, E)\\nImplies(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(B, D)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': True, 'error code': '(* There are logical relations that can help us infer the hypothesis. *)\\n(* There is a logical relation Implies(A, D), Implies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\") *)\\n(* Both A and D are from the explanation sentences. *)\\n(* We can infer TargetMutation e y from the premise. *)\\nthen have \"KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 Inhibit e \u2227 TargetMutation e y\" sledgehammer', 'solving time': 104.55376291275024, 'proof tactics': [], 'code': 'theory clinical_65_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PI3KAKT :: \"entity \u21d2 bool\"\\n  ActivationOfAkt :: \"entity \u21d2 bool\"\\n  Target :: \"entity \u21d2 bool\"\\n  Inhibit :: \"entity \u21d2 bool\"\\n  TargetPathway :: \"entity \u21d2 entity \u21d2 bool\"\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Related :: \"entity \u21d2 entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 entity \u21d2 bool\"\\n  SuppressionProliferation :: \"entity \u21d2 bool\"\\n  SuppressionSurvival :: \"entity \u21d2 bool\"\\n  CellularContext :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt *)\\naxiomatization where\\n  explanation_1: \"\u2200z. PI3KAKT z \u27f6 ActivationOfAkt z\"\\n\\n(* Explanation 2: The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway *)\\naxiomatization where\\n  explanation_2: \"\u2200z e. PI3KAKT z \u2227 Target e \u2227 Inhibit e \u2227 TargetPathway e z\"\\n\\n(* Explanation 3: The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor *)\\naxiomatization where\\n  explanation_3: \"\u2200x e. KinaseInhibitor x \u2227 Target e \u2227 TargetPathway e x \u2227 Related e x\"\\n\\n(* Explanation 4: The patient \"e\" involved in the inhibition process is associated with the mutations \"y\" *)\\naxiomatization where\\n  explanation_4: \"\u2200y e. Mutation y \u2227 Inhibit e \u2227 Patient e y\"\\n\\n(* Explanation 5: The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context *)\\naxiomatization where\\n  explanation_5: \"\u2200e. Target e \u2227 Inhibit e \u27f6 (SuppressionProliferation e \u2227 SuppressionSurvival e \u2227 CellularContext e)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z\"\\n  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival *)\\n shows \"\u2203x y z e. KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 Inhibit e \u2227 TargetMutation e y \u2227 TargetPathway e z \u2227 InhibitProliferation e \u2227 InhibitSurvival e\"\\nproof -\\n  (* From the premise, we have the known information about KinaseInhibitor, Mutation, Pathway, and PI3KAKT. *)\\n  from asm have \"KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z\" <ATP>\\n  (* There are logical relations that can help us infer the hypothesis. *)\\n  (* There is a logical relation Implies(A, D), Implies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\") *)\\n  (* Both A and D are from the explanation sentences. *)\\n  (* We can infer TargetMutation e y from the premise. *)\\n  then have \"KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 Inhibit e \u2227 TargetMutation e y\" <ATP>\\n  (* There is a logical relation Implies(B, E), Implies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context) *)\\n  (* Both B and E are from the explanation sentences. *)\\n  (* We can infer InhibitProliferation e \u2227 InhibitSurvival e from the premise. *)\\n  then have \"KinaseInhibitor x \u2227 Mutation y \u2227 Pathway z \u2227 PI3KAKT z \u2227 Target e \u2227 Inhibit e \u2227 TargetMutation e y \u2227 TargetPathway e z \u2227 InhibitProliferation e \u2227 InhibitSurvival e\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt\\nB: The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway\\nC: The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor\\nD: The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"\\nE: The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway)\\n--------\\nImplies(B, C)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor)\\n--------\\nImplies(C, D)\\nImplies(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(D, E)\\nImplies(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\", The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\n\\nDerived Implications:\\nImplies(B, E)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(A, E)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"), Not(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway))\\n--------\\nImplies(A, D)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(The patient \"e\" involved in the inhibition process is associated with the mutations \"y\"), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\nImplies(A, C)\\nImplies(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt, The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor)\\n--------\\nImplies(Not(E), Not(A))\\nImplies(Not(The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\nImplies(C, E)\\nImplies(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor, The inhibition of the pathway by the target \"e\" results in the suppression of proliferation and survival in the cellular context)\\n--------\\nImplies(B, D)\\nImplies(The concept of \"PI3KAKT z\" leads to the identification of a target \"e\" that may inhibit the pathway, The patient \"e\" involved in the inhibition process is associated with the mutations \"y\")\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(The agent \"e\" responsible for targeting the pathway is related to the entity \"x\" which represents the kinase inhibitor), Not(Introducing the concept of \"PI3KAKT z\" is a result of the activation of Akt))\\n--------\\n'}"
        ]
    }
}